Lataa...
Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar
The development of monoclonal antibodies has dramatically changed the outcome of patients with non-Hodgkin’s lymphoma (NHL), the most common hematological malignancy. However, despite the satisfying results of monoclonal antibody treatment, only few NHL patients are permanently cured with single-age...
Tallennettuna:
| Julkaisussa: | Pharmaceuticals (Basel) |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6958320/ https://ncbi.nlm.nih.gov/pubmed/31546999 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph12040141 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|